Pritpal Shinmar - LivaNova PLC Senior Vice President - Global Market Access
| LIVN Stock | USD 51.87 1.31 2.46% |
President
Mr. Pritpal Shinmar was appointed as Senior Vice President Global Market Access of the Company. He served as Global Market Access of the company. He is the current Vice President of Market Access of Sorin. Pritpal has 29 years of international healthcare industry experience, including in sales, marketing, strategic planning, business development, market development, Government Affairs, and HER. Prior to joining Sorin, Pritpal was Vice President, International Strategy, for Boston Scientific. During this time, he led the expansion into the emerging markets with focus on China and India. He also designed and implemented the international HER and Government Affairs teams to ensure timely generation and execution of value propositions for multiple healthcare stakeholders. Pritpal graduated from Trent University and has studied General Business Management at the London Business School. since 2015.
| Tenure | 9 years |
| Address | 20 Eastbourne Terrace, London, United Kingdom, W2 6LG |
| Phone | 44 20 3325 0660 |
| Web | https://www.livanova.com |
LivaNova PLC Management Efficiency
The company has return on total asset (ROA) of 0.0176 % which means that it generated a profit of $0.0176 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0141 %, meaning that it created $0.0141 on every $100 dollars invested by stockholders. LivaNova PLC's management efficiency ratios could be used to measure how well LivaNova PLC manages its routine affairs as well as how well it operates its assets and liabilities. As of the 17th of April 2024, Return On Tangible Assets is likely to grow to 0.01. Also, Return On Capital Employed is likely to grow to 0.05. At this time, LivaNova PLC's Intangible Assets are very stable compared to the past year. As of the 17th of April 2024, Net Tangible Assets is likely to grow to about 116.1 M, while Deferred Long Term Asset Charges is likely to drop about 4.8 M.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Michael Tarvin | Select Medical Holdings | 63 | |
| Michael Ussery | National HealthCare | 65 | |
| Martin Jackson | Select Medical Holdings | 69 | |
| Josh McCreary | National HealthCare | 51 | |
| John Saich | Select Medical Holdings | 55 | |
| Edmund Fay | Encompass Health Corp | 54 | |
| Brian Kidd | National HealthCare | 49 | |
| Linda Wilder | Encompass Health Corp | N/A | |
| Donald Daniel | National HealthCare | 67 | |
| David Lassiter | National HealthCare | 59 | |
| Frank Brown | Encompass Health Corp | N/A | |
| Julia Powell | National HealthCare | 68 | |
| R Ussery | National HealthCare | 60 | |
| John Lines | National HealthCare | 57 | |
| Patrick Darby | Encompass Health Corp | 56 | |
| Kevin Reese | The Ensign Group | N/A | |
| Jeffrey Smith | National HealthCare | 61 | |
| B Flatt | National HealthCare | 57 | |
| Jerry Gray | Encompass Health Corp | N/A | |
| Anderson Flatt | National HealthCare | 56 | |
| Thomas Mullin | Select Medical Holdings | 40 | |
Management Performance
| Return On Equity | 0.0141 | ||||
| Return On Asset | 0.0176 |
LivaNova PLC Leadership Team
Elected by the shareholders, the LivaNova PLC's board of directors comprises two types of representatives: LivaNova PLC inside directors who are chosen from within the company, and outside directors, selected externally and held independent of LivaNova. The board's role is to monitor LivaNova PLC's management team and ensure that shareholders' interests are well served. LivaNova PLC's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, LivaNova PLC's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Pritpal Shinmar, Senior Vice President - Global Market Access | ||
| Daniel Moore, Non-Executive Chairman of the Board | ||
| Stephanie Bolton, President Epilepsy | ||
| Alfred Novak, Independent Director | ||
| Arthur Rosenthal, Independent Director | ||
| Matthew III, Senior IT | ||
| Jacques Gutedel, President - Intercontinental | ||
| Deanna Wilke, Vice Communications | ||
| John Webb, Vice Epilepsy | ||
| Keyna Skeffington, Senior Vice President General Counsel | ||
| Francesco Bianchi, Independent Director | ||
| Demetrio Mauro, Chief Integration Officer | ||
| Sharon OKane, Independent Director | ||
| Vivid Sehgal, CFO | ||
| Hugh Morrison, Independent Director | ||
| Marco Dolci, Pres Unit | ||
| Lindsey Little, Director Relations | ||
| Damien McDonald, CEO Director | ||
| William Kozy, Chairman CEO | ||
| Brian Sheridan, Senior Vice President General Counsel, Company Secretary | ||
| David Wise, Chief Admin. Officer, Sr. VP and Secretary | ||
| AndreMichel Ballester, CEO, Executive Director | ||
| Andrea Saia, Non-Executive Independent Director | ||
| Badri Amurthur, Chief Officer | ||
| Michel Darnaud, President - Cardiac Surgery | ||
| Piero Vecchi, Vice President Controller | ||
| Trui Hebbelinck, Chief Human Resource Officer | ||
| Rohan Hoare, COO | ||
| Edward Andrle, Senior Vice President - Strategy & Business Development | ||
| Michael Hutchinson, Chief VP | ||
| Douglas Manko, Chief Accounting Officer | ||
| Ryan Miller, President Support | ||
| Stefano Gianotti, Independent Director | ||
| Thad Huston, CFO | ||
| Alex Shvartsburg, Chief Officer | ||
| Karen King, Vice President - Investor Relations and Corporate Communications | ||
| Bryan Olin, Senior Neuromodulation | ||
| Vladimir Makatsaria, CEO Director | ||
| Stefano Lullo, President - Cardiac Rhythm Management | ||
| Jonathan Walker, VP Segment |
LivaNova Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is LivaNova PLC a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0141 | ||||
| Return On Asset | 0.0176 | ||||
| Profit Margin | 0.02 % | ||||
| Operating Margin | 0.07 % | ||||
| Current Valuation | 3.25 B | ||||
| Shares Outstanding | 53.96 M | ||||
| Shares Owned By Insiders | 0.50 % | ||||
| Shares Owned By Institutions | 99.50 % | ||||
| Number Of Shares Shorted | 3.31 M | ||||
| Price To Earning | 78.67 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in LivaNova PLC. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. To learn how to invest in LivaNova Stock, please use our How to Invest in LivaNova PLC guide.You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Complementary Tools for LivaNova Stock analysis
When running LivaNova PLC's price analysis, check to measure LivaNova PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy LivaNova PLC is operating at the current time. Most of LivaNova PLC's value examination focuses on studying past and present price action to predict the probability of LivaNova PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move LivaNova PLC's price. Additionally, you may evaluate how the addition of LivaNova PLC to your portfolios can decrease your overall portfolio volatility.
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Stocks Directory Find actively traded stocks across global markets | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |
Is LivaNova PLC's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of LivaNova PLC. If investors know LivaNova will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about LivaNova PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 9.026 | Earnings Share 0.32 | Revenue Per Share 21.386 | Quarterly Revenue Growth 0.128 | Return On Assets 0.0176 |
The market value of LivaNova PLC is measured differently than its book value, which is the value of LivaNova that is recorded on the company's balance sheet. Investors also form their own opinion of LivaNova PLC's value that differs from its market value or its book value, called intrinsic value, which is LivaNova PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because LivaNova PLC's market value can be influenced by many factors that don't directly affect LivaNova PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between LivaNova PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if LivaNova PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, LivaNova PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.